Eltrombopag Peptide Mimetics
Overview
Eltrombopag is a small-molecule, non-peptide thrombopoietin receptor agonist that binds to the transmembrane domain of the thrombopoietin receptor, distinct from the natural ligand binding site. While not itself a peptide, it mimics thrombopoietin signaling to stimulate megakaryocyte proliferation and platelet production.
Mechanism of Action
The oral bioavailability of this synthetic agent addresses limitations of recombinant thrombopoietin peptides, which face immunogenicity challenges.
Research Summary & Key Findings
Eltrombopag received FDA approval in 2008 for chronic immune thrombocytopenia, with subsequent expansions for severe aplastic anemia and chronic hepatitis C-associated thrombocytopenia. The RAISE trial (NEJM, 2010) demonstrated significant platelet count increases and reduced bleeding events in chronic immune thrombocytopenia patients refractory to other therapies.
Clinical Status
Eltrombopag Peptide Mimetics has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Eltrombopag Peptide Mimetics"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Eltrombopag Peptide Mimetics"
Registered interventional and observational studies, including status and phase.
- PubChem — "Eltrombopag Peptide Mimetics"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hematology
Bivalirudin (Angiomax)
FDA ApprovedA synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and...
View detailsRomiplostim (Nplate)
FDA ApprovedA thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an...
View detailsPegcetacoplan (Empaveli)
FDA ApprovedA pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pa...
View detailsPeginesatide (Omontys)
FDA ApprovedPeginesatide is a synthetic pegylated peptide-based erythropoiesis-stimulating agent (ESA) consisting of two 21-amino ac...
View detailsStart Your Consultation
Get an AI-proposed Eltrombopag Peptide Mimetics protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Eltrombopag Peptide Mimetics.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.